Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Plain-language summary
This trial is testing brentuximab vedotin for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
brentuximab vedotin (DRUG): MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg. | brentuximab vedotin (DRUG): LyP Brentuximab vedotin 0.9 mg/kg2 | brentuximab vedotin (DRUG): MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
brentuximab vedotin, brentuximab vedotin, brentuximab vedotin
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details